CDC NEWS


powered by Surfing Waves


Latest News


Moderna applies for full F.D.A. approval for its Covid vaccine.


02 Jun 2021

Moderna on Tuesday became the latest pharmaceutical company to apply to the U.S. Food and Drug Administration for full approval for its Covid-19 vaccine for use in people 18 and older. F.D.A. approval would allow the company to market the shot directly to consumers, and could also help raise public confidence in the vaccine.


Seven European countries begin issuing a digital Covid certificate for travel.


02 Jun 2021

A digital Covid certificate system intended to ease travel within the European Union became operational in seven countries on Tuesday — ahead of schedule — offering a preview of what could become a standard for post-pandemic global mobility.


Delaying a COVID vaccine’s second dose boosts immune response


17 May 2021

Older people who waited 11–12 weeks for their second jab had higher peak antibody levels than did those who waited only 3 weeks.


An Updated Covid Guide For four different types of households.


17 May 2021

The new C.D.C. guidance has excited many Americans and scared many others. Some people feel both emotions, understandably enough: They’re excited to start returning to more normal daily life and still scared by a pandemic that is killing about 600 Americans a day. This morning, I want to think through the real-world implications of the new guidelines for individual families. Those guidelines mostly allow people to behave more freely. But they will also lead some to take new precautions. I am going to break down households into four categories, depending on vaccination status:


Breakthrough Infections Rare Among Vaccinated Americans


19 Apr 2021

In the United States, the Centers for Disease Control and Prevention provided its first public data about breakthrough Covid-19 cases to CNN last week and it shows that vaccines have been highly effective at reducing infections, hospitalizations and death. As of last week, around 78.5 million Americans had been fully vaccinated and the CDC's data states that 5,800 cases of Covid-19 occurred among fully vaccinated people, 396 of whom required hospitalization with 74 deaths recorded.




Articles


SARS-CoV-2 infection of the oral cavity and saliva


25 Mar 2021

Despite signs of infection—including taste loss, dry mouth and mucosal lesions such as ulcerations, enanthema and macules—the involvement of the oral cavity in coronavirus disease 2019 (COVID-19) is poorly understood. To address this, we generated and analyzed two single-cell RNA sequencing datasets of the human minor salivary glands and gingiva (9 samples, 13,824 cells), identifying 50 cell clusters. Using integrated cell normalization and annotation, we classified 34 unique cell subpopulations between glands and gingiva. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral entry factors such as ACE2 and TMPRSS members were broadly enriched in epithelial cells of the glands and oral mucosae. Using orthogonal RNA and protein expression assessments, we confirmed SARS-CoV-2 infection in the glands and mucosae. Saliva from SARS-CoV-2-infected individuals harbored epithelial cells exhibiting ACE2 and TMPRSS expression and sustained SARS-CoV-2 infection. Acellular and cellular salivary fractions from asymptomatic individuals were found to transmit SARS-CoV-2 ex vivo. Matched nasopharyngeal and saliva samples displayed distinct viral shedding dynamics, and salivary viral burden correlated with COVID-19 symptoms, including taste loss. Upon recovery, this asymptomatic cohort exhibited sustained salivary IgG antibodies against SARS-CoV-2. Collectively, these data show that the oral cavity is an important site for SARS-CoV-2 infection and implicate saliva as a potential route of SARS-CoV-2 transmission.




Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study


17 Mar 2021

The vast majority of people who recover from Covid-19 remain protective immunity from the virus for at least six months, researchers reported on Wednesday in a large study from Denmark. The study revealed protective immunity to be approximately 80–83% in people younger than 65 years. We found no difference in immunity over the study period. Among those aged 65 years and older, immunity was estimated to be approximately 47%.




SARS-CoV-2 Vaccines


26 Feb 2021

Shortly after SARS-CoV emerged at the turn of the 21st century, the spike (S) protein (particularly in its prefusion [native] conformation) was identified as the immunodominant antigen of the virus. Evaluation of patients with SARS-CoV-2 revealed that binding and neutralizing antibodies primarily target the receptor-binding domain of the S1 subunit.




SARS-CoV-2 Variants of Concern in the United States—Challenges and Opportunities


17 Feb 2021

. SARS-CoV-2, like other RNA viruses, constantly changes through mutation, with new variants occurring over time. Generally, when new variants become more common, they do so because of some selective advantage to the virus.




The US Regulatory System and COVID-19 Vaccines The Importance of a Strong and Capable FDA


15 Feb 2021

For many in public health and medicine, the coronavirus disease 2019 (COVID-19) pandemic in the US has been a frustrating journey from one disappointment to the next: late access to testing, insufficient staff and inadequate funding for contact tracing, jumbled communications, and, at the end of 2020, a chaotic launch of vaccination efforts.




Enroll for Free